// App-Quantinova.ai

1828 : Analysis of putative serum biomarker candidates for cardiotoxicity prediction in a cohort of early stage breast cancer patients treated with docetaxel, cyclophosphamide, and bevacizumab

Researchers

Presenter

  • David W. Murray

Principal Investigators

  • Alice C. OFarrell

  • Giuseppe Gullo

  • Ashwini Maratha

  • Patrick Dicker

  • Mairin Rafferty

  • Verena Murphy

  • Bonnie Ky

  • William M. Gallagher

  • Norma ODonovan

  • John Crown

  • Annette T. Byrne

Medical Centers

  • Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland

  • St Vincent's University Hospital, Dublin, Ireland

  • OncoMark Limited, Dublin, Ireland

  • Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland

  • Irish Cooperative Oncology Research Group, Dublin, Ireland

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • UCD School of Biomolecular and Biomedical Science, University College Dublin, Ireland

  • National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland

Locations

  • United States

  • Ireland

Companies

  • Oncomark Ltd

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Cardiotoxicity

  • Solid malignancies

Biomarkers

  • Myeloperoxidase

  • Endothelin-1

  • Galectin-3

  • Vascular endothelial growth factor A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • endothelin-1

  • Bevacizumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Angiomax (bivalirudin)

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved